The majority of human breast cancers exhibit luminal epithelial differentiation. However, most aggressive behavior, including invasion and purported cancer stem cell activity, are considered characteristics of basal-like cells. We asked the following questions: Must luminal-like breast cancer cells become basal-like to initiate tumors or to invade? Could luminally differentiated cells within a basally initiated hierarchy also be tumorigenic? To answer these questions, we used rare and mutually exclusive lineage markers to isolate subsets of luminal-like and basal-like cells from human breast tumors. We enriched for populations with or without prominent basal-like traits from individual tumors or single cell cloning from cell lines and recovered cells with a luminal-like phenotype. Tumor cells with basal-like traits mimicked phenotypic and functional behavior associated with stem cells assessed by gene expression, mammosphere formation and lineage markers. Luminallike cells without basal-like traits, surprisingly, were fully capable of initiating invasive tumors in NOD SCID gamma (NSG) mice. In fact, these phenotypically pure luminal-like cells generated larger and more invasive tumors than their basal-like counterparts. The tumorigenicity and invasive potential of the luminal-like cancer cells relied strongly on the expression of the gene GCNT1, which encodes a key glycosyltransferase controlling O-glycan branching. These findings demonstrate that basal-like cells, as defined currently, are not a requirement for breast tumor aggressiveness, and that within a single tumor there are multiple "stem-like" cells with tumorigenic potential casting some doubt on the hypothesis of hierarchical or differentiative loss of tumorigenicity.
The majority of human breast cancers exhibit luminal epithelial differentiation. However, most aggressive behavior, including invasion and purported cancer stem cell activity, are considered characteristics of basal-like cells. We asked the following questions: Must luminal-like breast cancer cells become basal-like to initiate tumors or to invade? Could luminally differentiated cells within a basally initiated hierarchy also be tumorigenic? To answer these questions, we used rare and mutually exclusive lineage markers to isolate subsets of luminal-like and basal-like cells from human breast tumors. We enriched for populations with or without prominent basal-like traits from individual tumors or single cell cloning from cell lines and recovered cells with a luminal-like phenotype. Tumor cells with basal-like traits mimicked phenotypic and functional behavior associated with stem cells assessed by gene expression, mammosphere formation and lineage markers. Luminallike cells without basal-like traits, surprisingly, were fully capable of initiating invasive tumors in NOD SCID gamma (NSG) mice. In fact, these phenotypically pure luminal-like cells generated larger and more invasive tumors than their basal-like counterparts. The tumorigenicity and invasive potential of the luminal-like cancer cells relied strongly on the expression of the gene GCNT1, which encodes a key glycosyltransferase controlling O-glycan branching. These findings demonstrate that basal-like cells, as defined currently, are not a requirement for breast tumor aggressiveness, and that within a single tumor there are multiple "stem-like" cells with tumorigenic potential casting some doubt on the hypothesis of hierarchical or differentiative loss of tumorigenicity. (2) (3) (4) . Despite the tempting extrapolation to luminal vs. basal cells-of-origin for luminal and basal-like breast cancer, respectively, there is increasing evidence to suggest that both subtypes originate from the luminal epithelial lineage (5) (6) (7) . However, once cancer is established, the only cancer stem cells so far described are essentially basal-like, and the majority of luminal cells within the tumors have been characterized as more differentiated and less malignant than basal cells (8, 9) . Adding more complexity is the report that metastatic lesions are enriched in luminal cells (9) . A popular explanation for these contradictions is the concept of tumor cell plasticity, i.e., the possibility that differentiated luminal cells must acquire basal-like traits to become malignant (10) (11) (12) (13) (14) . We set out to examine whether the above explanation always must be true or whether differentiated luminal-like breast cancer cells within a basally initiated hierarchy could be aggressive and stem-like in their own right.
To address these questions, we used two mutually exclusive markers, milk mucin (MM) and CD271, which identify subtypes of cells with either luminal-like differentiation or basal-like activity, respectively. MM was detected by the M18 antibody, which recognizes branched glycans (15) , whereas CD271/p75 NTR was detected by the ME20.4 antibody (16) . We show that frankly differentiated luminal-like cells without acquiring appreciable basallike traits can be aggressive and invasive when serially transplanted into NOD SCID gamma (NSG) mice or tested for invasiveness in Boyden chambers. Furthermore, that luminal-like cells derived from a stem-like, basal hierarchy cannot only be tumorigenic, but that they can also be more aggressive than their progenitors.
Results

CD271 and MM, Two Distinct Differentiation Markers of Normal Human Breast, Identify Distinct Subsets of Cells in Primary Tumors
and Cell Lines. In a search for distinct and rare candidates in both basal and luminal compartments, we used multicolor imaging of normal breast tissue, primary breast carcinomas and established cell lines stained with antibodies against a panel of markers, from which we selected two rare markers, CD271 (p75 NTR ) and MM (branched glycans, here abbreviated MM for 'milk mucin'). These two markers were selected carefully based on their lineage specificity in normal breast, cell surface location, trypsin insensitivity and expression in cultured cells, features that made them ideal for cell sorting and cloning applications (Fig. 1A Inset). Our initial staining of 53 biopsies of primary breast tumors revealed that CD271
+ cells were present in distinct single cells or small foci in 28 of 53 (53%) biopsies, of which 20 of 28 also contained distinct and nonoverlapping populations of MM + cells (Table S1) 1 ). Multicolor imaging revealed that whereas MM was part of a MUC1 + / K19 + compartment, CD271 often costained with p63, K17 and K5 albeit with the latter two exhibiting a more widespread pattern of staining in general, but usually in an essentially ER-and MM-negative background (Fig. S1 ). Based on these data, we used CD271 as the most stringent criterion for basallike activity, with p63 as an additional, facultative marker. To determine the relation between the two populations, we combined prospective isolation of cells with single cell cloning. FACS analysis of the MCF7 cell line readily allowed us to separate cells into CD271 + and MM + gates ( Fig. 2A ). Single-cell cloning efficiency was identical between the gates that allowed delineation of CD271 + and MM + cells (10-15%), and the expansion of single cells into "clones" required at least a month. That all clones indeed originated from single cells was verified by genomic profiling, and that these underwent essentially the same number of cell divisions before analysis was determined by evaluation of growth curves ( Fig. S2 A and B). Although interclonal variation was recorded, cultures derived from the CD271 + clones recapitulated a pattern of heterogeneity similar to that of the unsorted population, whereas cultures derived from MM + clones remained essentially negative for CD271 (Fig. 2A) . The first generation MM + clones also were negative for other basal-like activity measured including p63, CD44v6, Maspin, and K17 (Fig. S2C) cultures from MM + clones (Fig. 3A) . This was confirmed by quantitative real-time PCR (qRT-PCR) and extended by additional markers (Fig. 3B) . Several members of the canonical Wnt signaling pathway, shown to be associated with stem cell renewal (17) , and a subset of genes that were previously shown to be upregulated in CD44
+ cells (9) were high in the CD271 + clones (Fig. S3) . Expression of the miRNAs 205, 221, and 222, which correlate positively with maintenance of mammary epithelial progenitor cells in mice (18, 19) and ER negativity in breast cancer (20) , were strongly up-regulated in the CD271 + -derived cultures by miRNA microarrays (Fig. 3C Left) ; this result was confirmed by qRT-PCR (Fig. 3C Right) . We measured progenitor activity using the mammosphere assay, which purportedly measures "stemness" (21): CD271 + cells had enhanced mammosphere-forming capacity compared with MM + cells (Fig. 3D) . Thus, for all practical purposes only cells with a basal-like component exhibited stem-like characteristics. (Fig. 4B) . Surprisingly, however, we observed that the MM + -derived tumors grew substantially larger than the CD271 + -derived tumors and appeared invasive (Fig. 4C) . We confirmed the invasiveness of each of the populations using the Matrigel-coated transwell filter assay, and the MM + populations proved by far the most invasive (Fig. 4D) . We conclude that although there appears to be a differentiation hierarchy, this hierarchy does not confer progressive loss of tumor-initiating capacity and invasiveness. These properties do not diminish with differentiation; if anything, the opposite is true.
To understand the mechanism responsible for the MM + cells display the robust malignant phenotype, we investigated the role of expression of the branched glycan specific to MM cells. This glycan is detected by MAb M18, an antibody that has previously been identified as a differentiation marker of breast epithelium (22) . The primary gene controlling branching of O-glycans in breast epithelium is the core 2 synthase (core 2 β6GlcNAcT1) encoded by GCNT1. We therefore tested whether GCNT1 may play a role in the aggressiveness of the MM + subpopulation ( Fig.  4E and Fig. S4A ). Knockdown of GCNT1 did not interfere with expression of MUC1 as revealed by staining with the antibody 115D8 (Fig. S4B ). GCNT1 knockdown in cultures derived from a MM + clone of MCF7 dramatically delayed tumor formation in nude mice to a level comparable to the delay observed for cultures derived from CD271 + clones (Fig. 4F ); in addition, there was a significant reduction in the invasive capacity as measured by the Matrigel-coated transwell filter assay (arrow in Fig. 4D ). These data support the surprising conclusion that aggressiveness of MM + tumors is dependent on specific changes in glycosylation. the top genes identified by differential expression between CD271 + and MM + clones using significance analysis of microarrays (SAM). (Fig. 5A ; probes and genes listed in Dataset S1). In three independent datasets, we found that both CD271 + or MM + gene signatures predicted poor, relapse-free survival from breast cancer (P < 0.05) ( Fig. 5B and Fig. S5 A and B) . Remarkably, the relapse-free survival curves are almost identical whether one uses the CD271 + or the MM + signatures despite the fact that the two signatures are not related. As control, a specific gene set of highly expressed genes in parental MCF7, different from the CD271 + and MM + signatures, was not predictive of outcome in the same cohorts. Thus, both CD271-and MM-derived gene expression signatures show prognostic value.
Discussion
We have prospectively isolated two distinct populations of malignant cells, one basal-like and one luminal-like, forming a differentiation hierarchy in primary breast tumors as well as in diverse breast cancer cell lines. Both the population with the basallike and the luminal-like markers are tumor-initiating and invasive by all of the criteria measured. These data could be interpreted either in light of the cancer stem cell (CSC) model or the clonal evolution model (for review, see ref. 23 ). Our finding of a stemlike subpopulation, which by all measures appears to recapitulate the heterogeneity of the original population, would be expected within a CSC framework. Such prediction is a hallmark of the CSC hypothesis (8) . However, our results differ dramatically from the CSC model in that all of the populations tested within the differentiation hierarchy are tumor initiating at relatively low cell numbers in the more permissive NSG mice. One explanation for this apparent contradiction could be the possibility that differentiated cancer cells potentially convert into tumor-initiating CSCs in a reversible manner (11) . Breast CSCs are thought to be generally basal-like (9, 14) , implying that tumor formation would have to be initiated by cells with basal-like activity. By applying two narrowly expressed, mutually exclusive markers, MM and CD271, not used previously for breast CSC analysis, here we provide evidence compatible with a third, "fusion" model. CD271 has been described as a unique marker of melanoma stem cells in humans (24) . However, its first description in breast attributed it as a marker of myoepithelial cells (16) . More recent studies show that its overexpression strongly increases resistance to anti-tumoral TRAIL treatment (25) . The M18 antibody was shown to recognize branched glycans (15) and to stain apical membranes of luminal epithelial cells in the normal human breast (22) , but further specificity of its affinity remained to be investigated. Here we identify a linear connection between cells expressing these two nonoverlapping markers suggestive of at least a rudimentary differentiation lineage hierarchy in breast cancers-and surprisingly also in breast cancer cell lines. We show, however, that differentiation within this hierarchy not only does not decrease tumor-initiating capacity as predicted by the CSC model, but instead, the expanded sets of derivative cells appear to function as additional candidate cancer-initiating cells driving aggressive tumors. However, these cells are distinct from canonical stem cells in that they neither have undergone a detectable epithelial-to-mesenchymal transition, nor have they regressed to any particular dedifferentiated or basal-like state. These data require a revision to the existing hypotheses of breast cancer progression that can account for the observed contributions of multiple cell populations to tumor initiation.
Another unexpected finding in the present study is that basallike-or luminal-like-differentiation within subpopulations appears to not be limited to any particular subtype of breast cancer. In fact, we found rare basal-like cells even in bona fide primary luminal breast tumors or more surprisingly in breast cancer cell lines, such as MCF7, and found MM + luminally differentiated cells in bona fide primary basal tumors or basal tumor cell lines such as BT549. This could be interpreted either in favor of the classical view of cancer as a caricature of normal tissue renewal (26), or as transformation-induced basal/luminal-like reprogramming (27) . The first interpretation would have to rely on the assumption that breast cancer originates from normal stem cells. Candidate human breast stem cells have been reported repeatedly to be basal-primed by several of the markers used in the present study to characterize basal-like activity (9, 28) . It was shown recently in mice that adult tissue homeostasis does not rely on classical stem cells, but rather on self-duplication of lineage-restricted progenitors (29) . However, in contrast to mice, humans contain a substantial amount of K5
+ luminal breast epithelial cells, which is why basallike in the human breast is better defined by the concomitant expression of p63 and CD271. Nevertheless, if breast epithelial multipotency were limited to fetal life also in humans, and basallike activity in its most stringent CD271 + sense reflected cell-oforigin in cancer, it would imply that the earliest seeds of human breast cancer must exist in utero. Although increased susceptibility to breast cancer has been linked to the intrauterine origin (30) , the preponderance of data that suggest a luminal origin of most breast cancers favors the second option for generation of basal-like activity in breast cancers, i.e., postnatal or postpuberty reprogramming (5, 6) . This possibility includes that luminal cells should occasionally acquire a basal-like phenotype upon malignant transformation. We have shown previously that under certain culture conditions a small minority can convert to basal-like cells (31) . With the recent demonstration of in vivo self-duplication in the mouse mammary gland in mind (29) , it may be that culture conditions may unmask latent (or cryptic) potentials in luminal cells. Such distinctive expression of gene expression potentials between cells in vivo and cells in culture was summarized long ago and continues to be reported (32, 33) . In fact, it all comes down to microenvironmental cues and context because, even in vivo, mouse mammary gland luminal progenitors generate basal cells if exposed to a cleared fat pad (34, 35) .
Finally, the most intriguing finding of our investigation, apart from the fact that multiple cell types are tumor initiating, is the observation that both invasion and tumorigenicity of luminal-like breast cancer and breast cancer cell lines depended on GCNT1 expression, which is required for elaboration of the MM-specific branched glycan recognized by antibody M18 (15) . There is increasing appreciation that glycans play an important role in malignant behavior. Indeed, GCNT2 has been associated with breast cancer metastasis, and blocking its expression was shown to abrogate migration and invasion (36) .
In conclusion, our data implicate multiple types of tumorinitiating cells in breast cancers camouflaged in different phenotypic cloaks, including differentiated luminal-like cells. This particular finding is of profound clinical importance and strongly suggests the need for combinatorial therapies targeting multiple cell types in our search to prevent cancer recurrence or curb tumor aggressiveness while sparing the host. MCF7 cells were obtained and cultured as described (1), and BT474, and BT549 were purchased from ATCC. To avoid contaminating nonmalignant cells primary tumor-derived cultures were expanded for a while in short-term culture (STC) until purity with respect to tumor cells. STC defined as cultures expanded within the limits of a normal finite life span included HMT-3909 (STC1, passage 10) isolated as described (2), and L56Br-C1 (3) (STC2, passage 50), which was a kind gift from Professor Åke Borg (Lund University). Unless otherwise indicated, all media and supplements were purchased from Gibco. MCF7 cells were cultured in DME/F12 medium supplemented with 2mM glutamine, 50mg/mL gentamycin (Biological Industries), 5 μg/mL insulin (Sigma), and 5% FBS. BT474 cells were cultured in DMEM 1965 medium with glutamine, gentamycin, and 10% FBS, and BT549 cells were cultured in RPMI medium 1640 with glutamine, gentamycin, 1 mM sodium pyruvate, 2.5 mg/mL glucose and 10% FBS. HMT-3909 cells were cultured in CDM3 medium as described (4) with 20% FBS and L56Br-C1 cells were cultured in RPMI medium 1640 with glutamine, gentamycin, 7 NEA, 1 mM sodium pyruvate, 10 μg/mL insulin, and 10% FBS. All cells were cultured at 37°C in a humidified atmosphere with 5% CO 2 .
Materials and Methods
Cell Isolation, Staining, and Sorting. Tumor tissue was minced with scalpels and enzymatically digested by overnight incubation, except the xenografts by two hour incubation, in collagenase Type IV (900 units/mL, Worthington Biochemicals) in DMEM/F12 medium supplemented with 2 mM glutamine (Gibco), 50 mg/mL gentamycin and 5% FBS, at 37°C on a rotary shaker. Tumor cell aggregates were further dissociated into single cells with 0.25% trypsin/1mM EDTA for 10 min and sieve filtration through a 100-μm cell strainer. Short-term cultured tumor cells and cell lines were first trypsinized, filtered through a 10-μm cell strainer (BD Biosciences), before analysis with a FACSAria cell sorter (BD Biosciences) as described (4) Generally clones or enriched 'primary' tumor cells (STC1) were reanalyzed for e.g., multipotency after 4 wk, at which time they had undergone ∼11 population doublings and contained ∼2,000 cells.
Antibodies and Immunostaining. Cryostat sections of normal or tumor tissue as well as cultured cells were stained by immunoperoxidase or immunofluorescence as described (4, 5 4 primary cells (n = 5 biopsies) were plated in transmembrane chambers (8-μm pore size, 24-well plate format) coated with thinly layered Matrigel (Millipore) and supplemented with 0.5% FBS for cell lines and 5% FBS in CDM3 for primary cells. Generally, the lower chambers were supplemented with the growth media for cell lines and CDM3 medium with 20% FBS for primary tumor cells, and incubated for 4∼5 d except that BT549 was incubated for 2 d. To support migratory behavior, the BT474 cell growth medium was supplemented with 10 ng/mL hepatocyte growth factor (Sigma) and 1 μM progesterone (Sigma) 1 wk before performing the invasion assay. Invaded cells stained with 0.4% crystal violet in 50% ethanol were counted by light microscopy at 20× magnification by two observers using an ocular grid.
Single-cell mammosphere assay was performed as described (5) . MCF7 cells were cultured in MEGM medium with supplements and BT474 cells were cultured in regular growth medium in 96-well plates. The number of spheres was counted after 2 wk in culture. + cells were isolated by FACS from STC2 and transplanted into NSG mice (two inoculations in each group) and monitored for up to 15 wk. Before retransplantation, any dead cells were eliminated during sorting by PI-positivity and mouse cells were excluded by use of a mouse cell marker, H2Kd and/or human specific EpCAM. Tumorigenicity and the effect of GCNT1 silencing were assessed in 8-wkold BALB/c nu/nu female athymic mice. In general tumor take was low in nu/nu mice compared with NSG mice. A total 1 × 10 7 of MM + or CD271 + clones of MCF7 in suspension in PBS (150 μL) was s.c. transplanted at the fourth mammary gland with six inoculations in each group. 1 × 10 7 shGCNT1 or shControl (scrambled shRNA) treated MM + cells were tested with three inoculations in each group. Formation of tumors was assessed by palpation during the course of experiments (up to 15 wk).
RNA Isolation and mRNA/miRNA Expression Analysis. Total RNA was isolated using TRIzol Reagent (Invitrogen) and mRNAs of ΔNP63, SNAI2, TWIST, FN, and GAPDH were quantified using SYBR based qRT-PCR (iCycler, Bio-Rad) as previously described (5) . PCR conditions were the following: 3 min at 95°C, followed by 40 cycles of 95°C for 15 s and 60°C (55°C for POU5F1) at 45 s, followed by melting curve analysis. Additional primers that were used to quantify mRNA expression are following (F, forward; R, reverse): SOX2 F, ACAGCGCCCGCATGTACAACA; SOX2 R, ACGCGGTCCGGGCTGTTTTT; POU5F1 F, AGTGAGAGGCAACCTGGAGA; POU5F1 R, CAAAAACCCTGGCACAAACT; NANOG F, CAACTGGCCGAAGAATAGCA; NANOG R, GCAGGAGAATTTGGCTGGAA; JAG1 F, CTGTAAGAATCTCATTGCCAGCTA ; JAG1 R, ACACAGACACTGGAATCTGTTGAT ; KLF5 F, CCACCACCCTGCCAGTTAAC; KLF5 R, TAAACTTTTGTGCAACCAGGGTAA; CD44 F, GTCCCATACCACTCATGGATCT; CD44 R, CTTCTTCGACTGTTGACTGCAA; VIM F, CGAAAACACCCTGCAATCTT ; VIM R, TTGGCAGCCACACTTTCATA; CDH1 F, AGTGCCAACTGGACCATTCA; CDH1 R, TCTTTGACCACCGCTCTCCT; GCNT1 F, GATGTCACCTGGAATCAGCA; GCNT1 R, GCAGCAACGTCCTCAGCAT.
Each mean of expression of SOX2, POU5F1, NANOG, JAG1, KLF5, ΔNp63, CD44, TWIST, SNAI2, FN, VIM, and CDH1 in triplicate was calculated by the ΔΔCt method, using GAPDH as a normalized control and represented in a logarithmic scale. Mature miRNAs of hsa-miR-205, hsa-miR-221, hsa-miR-222 were quantified based on the stem-loop qRT-PCR, by using the Taqman MicroRNA assays, according to the manufacturer's protocol (Applied Biosystems). Data were presented in a logarithmic scale as the mean expression of two different experiments performed in triplicate, normalized to the endogenous RNU48 expression by the ΔΔCt method.
Microarray Experiments. For gene expression microarray analyses, samples included three cloned CD271 + cells (two different clones and FACS-sorted CD271 + from a clone) and four cloned MM + cells (three different clones and FACS-sorted MM + from a clone) of MCF7. RNA quality was confirmed using BioAnalyzer 2100 (Agilent Technologies). 400 ng total RNA was amplified and labeled using Agilent Low RNA Input Fluorescent Linear Amplification Kit and 1.65 μg of Cy3-labeled cRNA was hybridized onto Agilent Whole Human Genome Microarrays (4 × 44k, G4112F). For the miRNA analyses, 100 ng total RNA was labeled using the miRNA Microarray System (Agilent); two replicates of both a CD271 + clone and a MM + clone were hybridized onto Agilent Human miRNA Microarrays (G4470B) containing 723 human and 76 human viral miRNAs. Array-based CGH was performed using Agilent Human Genome CGH 244K Microarrays according to the manufacturer's protocol (1 μg of DNA was used as input). All arrays were scanned on an Agilent Microarray Scanner G2565A.
GCNT1 Silencing. We used pGIPZ (RHS4330, Openbiosystems) lentiviral vector expressing a short hairpin RNA (shRNAmir) to silence GCNT1 expression (mature sense sequence: GACACC-TGACGACTAT ATA) or a scrambled nontargeted shRNA (RHS 4346, Openbiosystems) as a negative control. Lentiviral production and cell transduction was previously described (5). Puromycin (2 μg/mL, Sigma) was used to select for stable cell lines. Cell lines with a transduction rate over 80% were used for further studies. The efficiency of the knockdown was confirmed by qRT-PCR with GCNT1 primers which mentioned above, normalized by GAPDH. Levels of sialyated MUC1 expression compared with MM expression in GCNT1 silenced and control populations were assessed by 115D8 by FACS (1:100, Biogenesis) and immunostaining (1:100), as described above.
Data Analysis and Statistics. Microarray gene expression data were preprocessed using Agilent Feature Extraction Software (v 9.5.3.1) using default settings. Furthermore, data were quantile normalized and filtered for spot quality using GeneSpring GX Software (Agilent) leaving 30705 probes for analysis. For averagelinkage hierarchical clustering analysis using Pearson distance measures, the genes were mean-centered. Cluster analyses were performed using Cluster (v 3.0) and displayed using Java Tree View (v 1.1.5r2). Genes significantly differentially expressed between MM + and CD271 + cells were identified using two-class, unpaired SAM with < 2.5% false discovery rate (FDR) (8) and 1025 genes were confirmed by differential expression distance synthesis (DEDS) (9) . The clustering and calculations for Fig. S5 were programmed in MATLAB. Fold change analysis of the miRNA microarray data used absolute ratio of the normalized intensities (no log scale) of two replicate experiments of each sample. For the CGH analysis, the raw data were extracted and normalized using Feature Extraction (v. 9.1.3.1, Agilent) and further processed and analyzed using CGH Explorer (http:// www.ifi.uio.no/forskning/grupper/bioinf/Papers/CGH/). Survival analysis was performed using the R package (10) survfit for Kaplan-Meier analysis with log-rank test. For the MicMa data (11), breast cancer specific death was used as endpoint; UNC data (12), relapse-free survival; Miller data (13), disease-specific survival. Mapping of probes between the three different breast tumor datasets (Agilent and Affymetrix platforms) was performed using the R package biomaRt (14) and numbers are illustrated in Fig. S5B .
Nonparametric Mann-Whitney tests were performed to measure the differences in mammosphere-forming capacity, tumor formation and invasiveness between CD271 + and MM + cells, by using R (v 2.13.0). Nine primary breast cancer samples, including 7 uncultured (PT8-14), which were selected from a repository of 28 additional samples based on positive staining for both CD271 and MM, and two short-term cultured primary carcinomas (STC1-2) were used for in vivo tumor-initiating in NSG mice. Three samples (PT13, STC1, and STC2) were successfully tumor initiating and used for further characterization of CD271 + and MM + cell behavior. -, no cells stained (stromal cells not included); +, any cancer cells stained; ++, two or more foci of cancer cells stained; low, no or faint staining in the majority of cells; high, strong staining in the majority of cells. 
